Abstract:Background Diabetic cardiovascular complication is a major cause of mortality in type 2 diabetic patients. Hyperglycemia markedly increases the risk of cardiovascular disease. Endothelial dysfunction is common in type 2 diabetes mellitus (DM) and is an early indicator of diabetic vascular disease. Therefore, it is necessary to identify the effect of different hypoglycemic agents on vascular endothelium. The aim of the study was to examine and compare the effects of metformin and gliquidone on atherosclerotic lesions in streptozotocin-induced diabetic rats. Methods Forty male Sprague-Dawley rats (age, 8 weeks; weight, 180–200 g) were included in this study and fed with a normal chow diet for 1 week. Rats (n=10) served as the normal control group (NC group) were fed with a normal chow for another 2 weeks and received an injection of saline. The rest 30 rats fed with a high-fat diet for 2 weeks and injected streptozotocin were randomly assigned to three groups (n=10 rats per group) as follow: type 2 DM group (DM group), DM + gliquidone group (GLI group) and DM + metformin group (MET group). Five weeks later, all rats were fasted overnight and taken tail blood samples for biochemical determinations. Then rats in the NC and DM groups were administrated with normal saline, while rats in the MET and GLI groups were administrated with metformin (100 mg/kg) or gliquidone (10 mg/kg), respectively. All medicines were given via intragastric administration for 8 weeks. After 16 weeks, plasma triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) were measured. The aortic arch was isolated from diabetic rats and was assessed by pathological sectioning using H&E staining. Results Metformin treatment prevented weight gain ((315.80±52.16) g vs. (318.70±68.48) g, P=0.773), improved plasma TG, HDL-C and LDL-C levels (P=0.006, 0.003, 0.001, respectively, all P <0.05). However, gliquidone showed no significant effects on plasma TG and TC levels (P=0.819, 0.053, respectively). LDL-C and HDL-C in the GLI group changed ((0.46±0.10) mmol/L vs. (0.36±0.14) mmol/L, P=0.007; (0.99±0.27) mmol/L vs. (1.11±0.18) mmol/L, P=0.049). Both metformin and gliquidone treatment lowered blood glucose levels (P=0.001, 0.004, respectively, P <0.05). Under light microscopy, no changes were observed in the aortic wall structure of each layer; the intima was smooth and the membrane elastic fibers were normal in the NC group. In the DM group, the aortic wall structure was unclear, the intima was thickened with irregular intima, and membrane elastic fibers collapsed. The aortic intima in the MET and GLI groups was smoother compared with the DM group, but the endothelial structure of the MET group was closer to that of the NC group. Conclusions Both metformin and gliquidone have anti-atherosclerotic effects. But the endothelial structure of the MET group was closer to that of the NC group. Metformin and gliquidone therapy can reduce serum level of LDL-C and increase level of HDL-C, whereas gliquidone therapy did not lose weight and decrease serum level of TG. These data may have important implications for the treatment of patients with type 2 DM.

Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein

Gliquidone Versus Metformin: Differential Effects on Aorta in Streptozotocin Induced Diabetic Rats

A Protective Role of Glibenclamide in Inflammation-Associated Injury

Gliclazide: Metabolic and vascular effects—A perspective

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Protective Effects of Gliclazide on High Glucose and AGEs-induced Damage of Glomerular Mesangial Cells and Renal Tubular Epithelial Cells Via Inhibiting RAGE-p22phox-NF-kB Pathway.

Evaluating Gliclazide Safety and Effectiveness in the Management of Type 2 Diabetes Mellitus

Glucagon-like Peptide-1 Receptor Agonist Dulaglutide Prevents Ox-Ldl-induced Adhesion of Monocytes to Human Endothelial Cells: an Implication in the Treatment of Atherosclerosis.

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells

Hepatoprotective potential of alpha-lipoic acid against gliclazide-induced liver injury in high-glucose-exposed human liver cells and experimental type 2 diabetic rats

Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis

Sulodexide reduces glucose induced senescence in human retinal endothelial cells

Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins

Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2

Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products.

Glycyrrhizin ameliorates vascular endothelial cell senescence by inhibiting HMGB1 in HFD/STZ-induced diabetic rats and human umbilical vein endothelial cells

SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol

Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials

Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines

Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process